CISPLATINO SANDOZ

DRUG4 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei Tumori, Humanitas Mirasole S.p.A.

Conditions

AdvancedMerkel cell carcinomasRecurrent Metastatic Nasopharingeal Carcinomalocally advanced cervical carcinomanaïvenon-small cell lung cancer

Phase 2

Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

RecruitingCTIS2022-502253-34-00

Fondazione IRCCS Istituto Nazionale Dei Tumorinon-small cell lung cancer

Start: 2023-09-11Target: 26Updated: 2023-05-02

Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).

RecruitingCTIS2022-500988-12-00

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione IRCCS Istituto Nazionale Dei TumoriAdvanced, Merkel cell carcinomas, naïve

Start: 2023-12-18Target: 35Updated: 2024-05-24

Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TRIAL

Not yet recruitingCTIS2025-521839-36-00

Fondazione IRCCS Istituto Nazionale Dei Tumorilocally advanced cervical carcinoma

Target: 29Updated: 2026-02-06

Phase 3

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

Not yet recruitingCTIS2025-522472-85-00

Humanitas Mirasole S.p.A.Recurrent Metastatic Nasopharingeal Carcinoma

Target: 49Updated: 2026-01-08